TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) - study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial

CONCLUSION: TIM-HHT will evaluate the efficacy and safety of timolol as an additional treatment of epistaxis in HHT patients in a three-month trial period. Benzalkonium chloride is used as a placebo, which has no documented positive effect on the nasal mucosa and hence on epistaxis in HHT patients (in contrast to saline).TRIAL REGISTRATION: German Clinical Trials Register (DRKS), DRKS00020994. Registered on 10 March 2020.PMID:34864649 | DOI:10.3233/CH-211253

Source: Clinical Hemorheology and Microcirculation - December 5, 2021 Category: Hematology Authors: Kornelia E C Andorfer Caroline T Seebauer Michael Koller Florian Zeman Mark Berneburg Ren é Fischer Veronika Vielsmeier Christopher Bohr Thomas S K ühnel Source Type: research